Description of blood Analysis: 

Chromogranin A (CgA) is a major soluble glycoprotein found within the secretory granules of neuroendocrine cells throughout the body. These cells are specialized to release hormones in response to neurological or chemical signals. When neuroendocrine cells become overactive or undergo tumor growth, they release increased amounts of Chromogranin A into the circulation. In clinical diagnostics, CgA is recognized as a sensitive and versatile “pan-neuroendocrine” tumor marker. Because it is secreted by many different types of neuroendocrine tissues, it serves as a primary tool for detecting, monitoring, and assessing the treatment response of various neuroendocrine tumors (NETs), regardless of which specific hormone the tumor might be producing.

What does the analysis represent?

• Purpose: To quantify a protein that serves as a general marker for neuroendocrine cell activity and tumor mass.
• Primary Application: Screening for and monitoring neuroendocrine tumors (such as carcinoid tumors, pheochromocytomas, or pancreatic islet cell tumors) and evaluating the effectiveness of oncological therapies.
• Method: Enzyme-Linked Immunosorbent Assay (ELISA) or Radioimmunoassay (RIA) using a venous blood sample.

Recommendations for the Test (General)

• Timing: Morning collection is generally preferred for consistency.
• Fasting: A 12-hour fast is required; water is permitted.
• Rest: Avoid intense physical exertion for 24 hours prior to the test.
• Specific Rules: Refrain from alcohol consumption for 24 hours. Most importantly, certain medications, specifically Proton Pump Inhibitors (PPIs) used for acid reflux (e.g., omeprazole, lansoprazole), can significantly elevate CgA levels. Discuss with your physician about stopping these medications 7–14 days before the test.

What can affect the results?

• Factors altering levels: Chronic use of acid-blocking medications (PPIs), chronic atrophic gastritis, and impaired kidney function are the most common causes of “false-positive” or elevated results.
• Conversely: Inflammatory bowel disease, liver disease, and heart failure can also lead to non-specific elevations in CgA concentrations.

When to take the test?

• Recommendations: This test is often requested when a physician suspects a neuroendocrine tumor due to symptoms like flushing, diarrhea, or wheezing, or to monitor patients already diagnosed with a NET.
• Preparation: The test should be performed when the patient is in a stable state and ideally after the clearance of any medications known to interfere with gastric acid production.

How to interpret the results?

• The interpretation of your laboratory results is the exclusive responsibility of a qualified physician.
• A Chromogranin A value should not be viewed in isolation; it is a non-specific marker that must be correlated with clinical symptoms and imaging.
• Your doctor will evaluate the result to differentiate between a tumor-related increase and an elevation caused by common medications or other underlying conditions.
• Only a professional medical review can integrate these findings with your clinical history to determine if further diagnostic steps are necessary.

Possible further investigations

• 5-HIAA (24-Hour Urine): To check for serotonin metabolites often associated with carcinoid tumors.
• Specific Hormone Panels: Such as Gastrin, Insulin, or Glucagon, depending on the suspected tumor site.
• Imaging Studies: Octreotide scans, Ga-68 DOTATATE PET/CT, or MRI to physically locate neuroendocrine lesions.
• Endocrinology or Oncology Consultation: To develop a comprehensive management and surveillance plan.

When does the next step make sense?

• If Chromogranin A levels are found to be persistently elevated after ruling out medication interference, the findings are reviewed by a physician to initiate specialized imaging or biopsy.
• All medical decisions are personalized based on the patient’s clinical presentation and tumor type.

👉 If necessary, you can discuss the analysis results with a specialist such as an endocrinologist (Doctors – TAMC), oncologist (Doctors – TAMC), or gastroenterologist (Doctors – TAMC).